Market CompetitionIncreasing competition from generic products continues to erode US sales, threatening the company's future revenue streams.
Profitability ConcernsA notable decline in gross margin, dropping significantly from previous levels, indicating potential long-term profitability issues.
Revenue DeclineThe introduction of icosapent ethyl generics is leading to significant price pressures, resulting in a substantial decline in revenue per prescription.